Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02202044 · ClinicalTrials.gov registry record · NA
Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection
A NA study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT02202044 is a NA study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 13 participants.
The verdict
NCT02202044, a NA study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the bladder cancer recurrence free rate, according to a phase II pilot study, of intravesical instillation of sequential BCG and EMDA/MMC after TUR. The study is designed as a one-sample investigation: the outcome measure is disease recurrence rate. Follow up will continue up to 5 years. For sample size determination, disease recurrence rate will be compared with literature data of recurrence rate obtained in standard BCG alone administration (Lamm's protocol).
Interventions
- DEVICE Intravesical BCG and EMDA/MMC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-02-24 |
| Est. Completion | 2016-05-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02202044
The ClinicalTrials.gov registry entry for NCT02202044 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravesical BCG and EMDA/MMC is the first listed.
NCT02202044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02202044 about?
NCT02202044 is a clinical study titled "Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection". The primary objective of the study is to assess the bladder cancer recurrence free rate, according to a phase II pilot study, of intravesical instillation of sequential BCG and EMDA/MMC after TUR. The study is designed as a one-sample investigation: the outcome measure is disease recurrence rate. Fo...
What is the current status of trial NCT02202044?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2015-02-24. Estimated completion is 2016-05-11.
What interventions are being tested in trial NCT02202044?
The interventions under investigation include: Intravesical BCG and EMDA/MMC (DEVICE).
Who is sponsoring clinical trial NCT02202044?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.